NCT00573261View on ClinicalTrials.gov

A Randomized Double-Blind Study Testing the Effects of Pregabalin on Diabetic Neuropathy

PHASE4CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

March 31, 2006

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Diabetic Neuropathy
Interventions
DRUG

Pregabalin

Subjects will take pregabalin for the duration of four weeks. The dosage will range from 75 mg twice a day to 300 mg twice a day.

DRUG

Placebo

Subjects will take placebo for the duration of four weeks. The dosage will range from 75 mg twice a day to 300 mg twice a day.

Trial Locations (1)

27710

Duke University Medical Center, Durham

Sponsors

Lead Sponsor

Duke University

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

lead

Duke University

OTHER

NCT00573261 - A Randomized Double-Blind Study Testing the Effects of Pregabalin on Diabetic Neuropathy | Biotech Hunter | Biotech Hunter